Table 2.

BNT162b2 COVID-19 vaccine responder rates according to anticancer treatment.

Type of tumor	Responders	Non-responders
	43 (86%)	7 (14%)
Breast cancer	37 (74%)	7 (14%)
•Therapy in an early setting	12 (24%)	7 (14%)
Anthracycline-based chemotherapy	8 (16%)	7 (10%)
Target therapy	4 (8%)	0 (0%)
•Therapy for advanced disease	25 (50%)	0 (0%)
Anthracycline-based chemotherapy	0 (0%)	0 (0%)
Non-anthracycline-based chemotherapy	9 (18%)	0 (0%)
Target therapy	16 (32%)	0 (0%)
Gynecological tumor	6 (12%)	0 (0%)
•Therapy in early setting	2 (4%)	0 (0%)
• Non-anthracycline-based chemotherapy	2 (4%)	0 (0%)
•Therapy for advanced disease	4 (8%)	0 (0%)
• Non-anthracycline-based chemotherapy	2 (4%)	0 (0%)
Target therapy	2 (4%)	0 (0%)